AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18652328 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 62
Study 17160910 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP IV inhibitors (gliptins)
Number of subjects: 0
Study 12532097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily
Number of subjects: 0
Study 12532097 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 250 microg administered twice daily
Number of subjects: 0
Study 11233712 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of azelastine and beclomethasone administered together (morning and evening, with a 5-minute interval)
Number of subjects: 219
Study 11233712 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of azelastine and beclomethasone administered separately (azelastine in the morning and evening, beclomethasone later during the morning and in the afternoon)
Number of subjects: 219
Study 11233712 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of azelastine and beclomethasone
Number of subjects: 219
Study 8895908 — intervention group
Group type: EXPERIMENTAL
Intervention: 89Sr (148 MBq) followed by carboplatin (100 mg m‐2 at 7 and 21 days)
Number of subjects: 30
Study 8895908 — intervention group
Group type: COMPARATOR
Intervention: 89Sr alone
Number of subjects: 30
Study 8895908 — intervention group
Group type: EXPERIMENTAL
Intervention: 89Sr and carboplatin
Number of subjects: 30
Study 1900379 — intervention group
Group type: EXPERIMENTAL
Intervention: deferoxamine (chelation therapy)
Number of subjects: 31
Study 1900379 — intervention group
Group type: COMPARATOR
Intervention: no chelation therapy (control group)
Number of subjects: 31
Study 6198367 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin and metronidazole
Number of subjects: 36
Study 6198367 — intervention group
Group type: COMPARATOR
Intervention: cefuroxime and metronidazole
Number of subjects: 36
Study 31764095 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir disoproxil fumarate (TDF) for preexposure prophylaxis (PrEP)
Number of subjects: 33
Study 31764095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 29357843 — intervention group
Group type: EXPERIMENTAL
Intervention: Women for Women International (WfWI) intervention, a year-long combined economic and social empowerment program.
Number of subjects: 0
Study 29357843 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 28243779 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 13
Study 28243779 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 13
Study 24747867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with peginterferon alfa-2a 135 μg/week plus ribavirin 200 mg/day (n=86)
Number of subjects: 172
Study 24747867 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2a 135 μg/week (n=86)
Number of subjects: 172
Study 24747867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 172
Study 24747867 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 172
Study 24473718 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrices (0-275, 275-550, 550-1,100 µg F/g)
Number of subjects: 0
Study 24473718 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrices (1,100 µg F/g)
Number of subjects: 0
Study 21632123 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth breathing during childhood (SG)
Number of subjects: 24
Study 21632123 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study 18280833 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care Pathway (ICP)
Number of subjects: 298
Study 18280833 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 298
Study 16199429 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 143
Study 16199429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 16199429 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 143
Study 16199429 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss through lifestyle changes
Number of subjects: 143
Study 12955343 — intervention group
Group type: EXPERIMENTAL
Intervention: NEAT device
Number of subjects: 24
Study 12955343 — intervention group
Group type: COMPARATOR
Intervention: Reliance Insert
Number of subjects: 24
Study 10934930 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol and midazolam coinduction
Number of subjects: 80
Study 10934930 — intervention group
Group type: COMPARATOR
Intervention: Control group (first group)
Number of subjects: 80
Study 10934930 — intervention group
Group type: COMPARATOR
Intervention: Control group (third group)
Number of subjects: 80
Study 10934930 — intervention group
Group type: COMPARATOR
Intervention: Control group (fourth group)
Number of subjects: 80
Study 9058494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid administered intravenously at the end of the operation, repeated three hours later.
Number of subjects: 24
Study 9058494 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered to control group.
Number of subjects: 24
Study 9058494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (I)
Number of subjects: 24
Study 9058494 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 24
Study 8477179 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 17
Study 8477179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3718586 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam (0.25 mg)
Number of subjects: 0
Study 3718586 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 0
Study 3718586 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 3718586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31633576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg/kg)
Number of subjects: 20
Study 31633576 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.1 ml/kg)
Number of subjects: 20
Study 30526533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional Polynomials (FP) transformations
Number of subjects: 4479
Study 30526533 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted Cubic Splines (RCS) transformations
Number of subjects: 4479
Study 30526533 — intervention group
Group type: COMPARATOR
Intervention: Dichotomized predictors
Number of subjects: 4479
Study 30526533 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorized predictors into three or four groups
Number of subjects: 4479
Study 30526533 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation set models based on FP and RCS transformations
Number of subjects: 4479
Study 27684878 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (effective effect-site concentration for 50% [EC50])
Number of subjects: 48
Study 27684878 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (effective effect-site concentration for 95% [EC95])
Number of subjects: 48
Study 24743662 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Love intervention, a 3-4 hour interactive educational workshop
Number of subjects: 0
Study 24743662 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored, interactive group intervention efforts
Number of subjects: 0
Study 23298894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile GnRH therapy
Number of subjects: 30
Study 23298894 — intervention group
Group type: COMPARATOR
Intervention: Combined gonadotropins (rFSH+rLH)
Number of subjects: 30
Study 21934521 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipo‐PGE1 (20 μg/day intravenously for 5 days)
Number of subjects: 79
Study 21934521 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (control group)
Number of subjects: 79
Study 18600212 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic ABP
Number of subjects: 1167
Study 18600212 — intervention group
Group type: COMPARATOR
Intervention: Systolic CBP
Number of subjects: 1167
Study 18600212 — intervention group
Group type: COMPARATOR
Intervention: Systolic UBP
Number of subjects: 1167
Study 16941968 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive program of acupuncture, moxibustion and massage
Number of subjects: 660
Study 16941968 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive program of physical therapy
Number of subjects: 660
Study 14570664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine sulfate (ITMS) 0.1 mg
Number of subjects: 80
Study 14570664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine sulfate (ITMS) 0.2 mg
Number of subjects: 80
Study 14570664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine sulfate (ITMS) 0.3 mg
Number of subjects: 80
Study 14570664 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine sulfate (ITMS) 0.0 mg (control)
Number of subjects: 80
Study 14570664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine sulfate (ITMS) (0.1, 0.2, 0.3 mg)
Number of subjects: 80
Study 14570664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine sulfate (ITMS) (0.2 mg)
Number of subjects: 80
Study 10761163 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen controlled-release (CR) sprinkles on applesauce
Number of subjects: 112
Study 10761163 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen immediate-release (IR) elixir
Number of subjects: 112
Study 8881732 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐expanding metal stents
Number of subjects: 474
Study 8881732 — intervention group
Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 474
Study 8881732 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (epirubicin, cisplatin, and 5‐fluorouracil)
Number of subjects: 474
Study 1553892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil hydrochloride (HCl) at a mean maintenance dosage of 324 mg/day
Number of subjects: 75
Study 1553892 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol HCl
Number of subjects: 75
Study 1553892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil combined with propranolol
Number of subjects: 75
Study 1553892 — intervention group
Group type: COMPARATOR
Intervention: Propranolol plus placebo
Number of subjects: 75
Study 3296615 — intervention group
Group type: EXPERIMENTAL
Intervention: DDS 100 mg 7/7 for 3 years
Number of subjects: 75
Study 3296615 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP 900 mg 1/7 for 8 doses
Number of subjects: 75
Study 3296615 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP 900 mg 7/7 for 12 doses
Number of subjects: 75
Study 29551889 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐asarone 10 mg/d, tenuigenin 10 mg/d, and memantine 5‐20 mg/d
Number of subjects: 152
Study 29551889 — intervention group
Group type: COMPARATOR
Intervention: memantine 5‐20 mg/d
Number of subjects: 152
Study 27973594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 0
Study 27973594 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 0
Study 25405764 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal iron status
Number of subjects: 2443
Study 25405764 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasite infection
Number of subjects: 2443
Study 25405764 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 2443
Study 25405764 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia, iron, zinc, iodine, and vitamin A deficiency
Number of subjects: 2443
Study 21699760 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic technique
Number of subjects: 60
Study 21699760 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini‐invasive technique
Number of subjects: 60
Study 21699760 — intervention group
Group type: COMPARATOR
Intervention: Classical technique
Number of subjects: 60
Study 15704687 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianlie Sanyu Capsule
Number of subjects: 72
Study 15704687 — intervention group
Group type: COMPARATOR
Intervention: Longbishu
Number of subjects: 72
Study 11898913 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin prophylaxis
Number of subjects: 0
Study 11898913 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancy
Number of subjects: 0
Study 9533118 — intervention group
Group type: EXPERIMENTAL
Intervention: Terumo Capiox SX25 (2.5 m2)
Number of subjects: 0
Study 9533118 — intervention group
Group type: COMPARATOR
Intervention: Terumo Capiox SX18 (1.8 m2)
Number of subjects: 0
Study 8077472 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical propylthiouracil (PTU), applied three times daily for 4 to 8 weeks
Number of subjects: 9
Study 8077472 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 9
Study 2916335 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micron micro‐aggregate filter
Number of subjects: 11
Study 2916335 — intervention group
Group type: COMPARATOR
Intervention: 170‐micron giving set filter
Number of subjects: 11
Study 1087743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (KETO), 200 mg daily
Number of subjects: 12
Study 1087743 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA), 3.6 g daily
Number of subjects: 12
Study 1087743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 12532056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing glass ionomer cement
Number of subjects: 21
Study 12532056 — intervention group
Group type: COMPARATOR
Intervention: Composite resin (no fluoride)
Number of subjects: 21
Study 30269644 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (A‐tDCS)
Number of subjects: 14
Study 30269644 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (S‐tDCS)
Number of subjects: 14
Study 26652797 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of quadrivalent HPV vaccine on days 1, 60, and 180 or later
Number of subjects: 17729
Study 26652797 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of quadrivalent HPV vaccine on days 1 and 180 or later
Number of subjects: 17729
Study 26652797 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of quadrivalent HPV vaccine on days 1 and 60 by default
Number of subjects: 17729
Study 26652797 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of quadrivalent HPV vaccine by default
Number of subjects: 17729
Study 26652797 — intervention group
Group type: COMPARATOR
Intervention: All groups tested for incident HPV infections
Number of subjects: 17729
Study 26652797 — intervention group
Group type: COMPARATOR
Intervention: Testing of cervical samples from participants
Number of subjects: 17729
Study 24613188 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg sildenafil citrate
Number of subjects: 90
Study 24613188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22266602 — intervention group
Group type: EXPERIMENTAL
Intervention: GVO+NSBB
Number of subjects: 95
Study 22266602 — intervention group
Group type: COMPARATOR
Intervention: GVO alone
Number of subjects: 95
Study 20633189 — intervention group
Group type: EXPERIMENTAL
Intervention: Active eradication therapy
Number of subjects: 30
Study 20633189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18532873 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision in HIV-positive men
Number of subjects: 2746
Study 18532873 — intervention group
Group type: COMPARATOR
Intervention: Male circumcision in HIV-negative men
Number of subjects: 2746
Study 18532873 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumption of intercourse before wound healing
Number of subjects: 2746
Study 15378284 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes with MRAs
Number of subjects: 39
Study 15378284 — intervention group
Group type: COMPARATOR
Intervention: Athletes without MRAs
Number of subjects: 39
Study 12442020 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal conjugate vaccine (n = 250)
Number of subjects: 500
Study 12442020 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 250)
Number of subjects: 500
Study 10373132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1 mg twice daily for three nights and 500 microg twice daily for 11 nights
Number of subjects: 50
Study 10373132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8570977 — intervention group
Group type: EXPERIMENTAL
Intervention: On-waterbed (On-WB)
Number of subjects: 22
Study 8570977 — intervention group
Group type: COMPARATOR
Intervention: Baseline (standard incubator mattress)
Number of subjects: 22
Study 8570977 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-waterbed (Off-WB)
Number of subjects: 22
Study 2240627 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane with 60% N2O
Number of subjects: 270
Study 2240627 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane without N2O
Number of subjects: 270
Study 365325 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 62
Study 365325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 30971279 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimisation strategies for recruitment including adjustments to recruitment processes, additional recruiting sites, and a projection equation for recruitment estimates.
Number of subjects: 0
Study 28501541 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 0
Study 28501541 — intervention group
Group type: COMPARATOR
Intervention: Sacral Neuromodulation
Number of subjects: 0
Study 25474566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 15
Study 25474566 — intervention group
Group type: COMPARATOR
Intervention: Control (no IPC)
Number of subjects: 15
Study 23549825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully deflated LMA insertion
Number of subjects: 172
Study 23549825 — intervention group
Group type: COMPARATOR
Intervention: Partially inflated LMA insertion
Number of subjects: 172
Study 21624883 — intervention group
Group type: EXPERIMENTAL
Intervention: HibMenCY vaccine
Number of subjects: 4180
Study 21624883 — intervention group
Group type: COMPARATOR
Intervention: Hib conjugate vaccine (ActHIB) and PedvaxHIB
Number of subjects: 4180
Study 19435396 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated voice message intervention
Number of subjects: 0
Study 19435396 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy‐led outreach intervention
Number of subjects: 0
Study 19435396 — intervention group
Group type: COMPARATOR
Intervention: Electronic medical record reminder intervention
Number of subjects: 0
Study 19435396 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 16454149 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific acupressure treatment
Number of subjects: 0
Study 16454149 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure treatment
Number of subjects: 0
Study 16454149 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study 15001401 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT
Number of subjects: 136
Study 15001401 — intervention group
Group type: COMPARATOR
Intervention: ConvRad
Number of subjects: 136
Study 11731064 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0mg morphine-HCl
Number of subjects: 53
Study 11731064 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1mg morphine-HCl
Number of subjects: 53
Study 11731064 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 53
Study 9041945 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rHuGH) for 1 year
Number of subjects: 18
Study 9041945 — intervention group
Group type: COMPARATOR
Intervention: Control levels (not specified)
Number of subjects: 18
Study 8185094 — intervention group
Group type: COMPARATOR
Intervention: Room air ventilation (baseline)
Number of subjects: 13
Study 8185094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula (at 10 L/min)
Number of subjects: 13
Study 8185094 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supply tubing (at 15 L/min)
Number of subjects: 13
Study 8185094 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand valve
Number of subjects: 13
Study 3503941 — intervention group
Group type: EXPERIMENTAL
Intervention: Information booklet
Number of subjects: 0
Study 3503941 — intervention group
Group type: COMPARATOR
Intervention: Control group (no booklet)
Number of subjects: 0
Study 29364772 — intervention group
Group type: EXPERIMENTAL
Intervention: iCanDecide interactive and tailored Web site
Number of subjects: 537
Study 29364772 — intervention group
Group type: COMPARATOR
Intervention: iCanDecide static Web site (control)
Number of subjects: 537
Study 27221217 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air warming (active warming)
Number of subjects: 140
Study 27221217 — intervention group
Group type: COMPARATOR
Intervention: Usual care (passive warming with heated cotton blankets)
Number of subjects: 140
Study 25135364 — intervention group
Group type: EXPERIMENTAL
Intervention: Viable and revascularized before follow-up echocardiogram
Number of subjects: 224
Study 25135364 — intervention group
Group type: EXPERIMENTAL
Intervention: Viable, but medically treated
Number of subjects: 224
Study 25135364 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-viable patients
Number of subjects: 224
Study 23834410 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil (group PR) - 56 μg/kg/min of propofol and 0.06 μg/kg/min of remifentanil
Number of subjects: 120
Study 23834410 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (group S) - 1.3 MAC
Number of subjects: 120
Study 23834410 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil (group PR)
Number of subjects: 120
Study 23834410 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (group S)
Number of subjects: 120